Koichi Takahashi from the MD Anderson Cancer Center discusses two abstracts presented at 60th Annual Society of Hematology Annual Meeting and Exposition, which focused on the clonal evolution of acute myeloid leukemia (AML) during treatment. He highlighted that clonal heterogeneity plays a key role in the relapse from IDH inhibitor treatment.
IDH1/2, General AML
Koichi Takahashi | ASH 2018 | Clonal heterogeneity of AML and its evolution at relapse
Was this article informative? Thank you for your feedback!